Grant Details

GRANT OVERVIEW

Grant name and funding organization

Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)

National Institutes of Health (NIH)

Total funding amount and duration

Funding amounts are not limited but should reflect the actual needs of the proposed project.

UG3 phase duration is up to 1 year; UH3 phase duration is expected to be 4 years, with a possibility of up to 6 years with strong justification.

Primary objective and mission statement

To develop and implement a Clinical Coordinating Center for multi-site clinical trials.

Focus on trials relevant to the research mission of the NHLBI, including innovative designs and addressing health disparities.

Key stakeholders and beneficiaries

National Heart, Lung, and Blood Institute (NHLBI)

Participants in clinical trials, including diverse populations.

ELIGIBILITY CRITERIA

Organization Requirements

Eligible organization types include higher education institutions, nonprofits, for-profit organizations, local/state/county governments, and tribal governments.

Foreign organizations are also eligible to apply.

Geographic Scope

Open to U.S. and non-U.S. entities, including foreign organizations.

Project Requirements

Must propose clinical trials that meet NIH definitions and are relevant to NHLBI's mission.

Trials must include multi-site recruitment and address community engagement.

Financial Requirements

No specific budget limits, but budgets must reflect actual project needs.

Direct costs of $500,000 or more require prior consultation with NIH.

Timeline Requirements

Applications are due by September 11, 2025.

UG3 phase expected to start by February 11, 2025.

Previous Funding Considerations

Applicants may submit multiple applications as long as they are scientifically distinct.

Applications must be part of a collaborative pair with a DCC application.

APPLICATION PROCESS

Required documentation and materials

Applications must include a Trial Management Plan, Clinical Trial Research Experience, and a Community Engagement Plan.

Evaluation criteria and scoring system

Applications will be evaluated based on significance, innovation, rigor, and feasibility.

Review process and timeline

Applications undergo peer review and are evaluated for scientific and technical merit.

Selection criteria and priorities

Applications that address health disparities and include diverse participant recruitment will be prioritized.

SPECIAL CONSIDERATIONS

Unique aspects or requirements

Must collaborate with a Data Coordinating Center (DCC) application.

Potential challenges or limitations

Meeting recruitment and retention milestones is critical for funding continuation.

Strategic alignment opportunities

Encouraged to leverage existing clinical trial networks.

Competitive advantages or disadvantages

Strong emphasis on community engagement may provide a competitive edge.

KEY INSIGHTS AND RECOMMENDATIONS

Critical success factors

Demonstrating experience in multi-site clinical trials and effective project management.

Common pitfalls to avoid

Failing to meet core milestones and not addressing community engagement adequately.

Strategic recommendations for applicants

Engage with NHLBI staff early in the application process for guidance.

Competitive positioning advice

Highlight innovative trial designs and community engagement strategies.

Grant Details

clinical trials health disparities community engagement multi-site trials NHLBI research public health cooperative agreement investigator-initiated
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
PAR-25-029
National Institutes of Health
EDU NGO PUBLIC ENTERPRISE OTHER
US AF AL DZ AS AD AO AI AQ AG AR AU AT BY BE BG CA CN HR CY CZ DK EG EE FI FR GE DE GI GR HU IS IE IL IT JP LV LI LT LU MK MY MT MX MD NL NZ NO PL PT QA RO SA SC SG SK SI ES SE CH TR UA AE UK VA VG VI
RESEARCH_DEVELOPMENT
True
None
None
None
USD
None
True
True
Expected to contribute to the evidence base for important health matters and reduce health inequities.
Completion of core milestones, including recruitment and retention goals.
Sept. 11, 2025, 10 p.m.
Not specified
Trial Management Plan, Clinical Trial Research Experience, Community Engagement Plan.
True
Applications will be evaluated based on significance, innovation, rigor, and feasibility.
Applications must demonstrate innovative trial designs.
Applications must address the feasibility of meeting recruitment and retention milestones.
Applications must show potential for significant health impact.
True
True
Cooperative Agreement
Recipients must comply with all terms and conditions outlined in the Notice of Award.
Regular progress reports and adherence to milestone completion.
Details of payment arrangements will be specified in the Notice of Award.
All NIH grants policies apply.
Must comply with NIH policies regarding clinical trials.